Penn Center for Myeloproliferative Neoplasms

Edward A. Stadtmauer

faculty photo

Edward A. Stadtmauer

Roseman, Tarte, Harrow, and Shaffer Families' President's Distinguished Professor
Department: Medicine

Contact information
Division of Hematology Oncology
Perelman Center for Advanced Medicine
12th Floor, South Pavilion
Office #12-171
3400 Civic Center Blvd
Philadelphia, PA 19104
Office: 215-662-7910
Fax: 215-615-5888
A.B. (Biochemistry)
Cornell University, College of Arts and Sciences, 1979.
M.D. (Medicine)
University of Pennsylvania School of Medicine, 1983.
Permanent link
> Perelman School of Medicine   > Faculty   > Details

Description of Research Expertise

Clinical trials, Bone Marrow Transplant

Description of Clinical Expertise

Myeloma, Leukemia, Lymphoma and Bone Marrow and Stem Cell Transplant

Selected Publications

Connor MP, Loren AW, Hexner EO, Martin ME, Gill SI, Luger SM, Mangan JK, Perl AE, McCurdy SR, Pratz KW, Timlin C, Freyer CW, Carulli A, Catania C, Smith J, Hollander L, Zebrowski AM, Stadtmauer EA, Porter DL, Frey NV.: Clofarabine and busulfan myeloablative conditioning in allogeneic hematopoietic cell transplant for patients with active myeloid malignancies. Transplant Cell Ther Nov 2022.

Dhodapkar KM, Cohen AD, Kaushal A, Garfall AL, Manalo RJ, Carr AR, McCachren SS, Stadtmauer EA, Lacey SF, Melenhorst JJ, June CH, Milone MC, Dhodapkar MV.: Changes in Bone Marrow Tumor and Immune Cells Correlate with Durability of Remissions Following BCMA CAR T Therapy in Myeloma. Blood Cancer Discov 3: 490-501, Nov 2022.

Lonial S, Popat R, Hulin C, Jagannath S, Oriol A, Richardson PG, Facon T, Weisel K, Larsen JT, Minnema MC, Abdallah AO, Badros AZ, Knop S, Stadtmauer EA, Cheng Y, Amatangelo M, Chen M, Nguyen TV, Amin A, Peluso T, van de Donk NWCJ.: Iberdomide plus dexamethasone in heavily pretreated late-line relapsed or refractory multiple myeloma (CC-220-MM-001): a multicentre, multicohort, open-label, phase 1/2 trial. Lancet Haematol Nov 2022.

Broglie L, Friend BD, Chhabra S, Bupp C, Schiller GJ, Logan B, Pasquini MC, Savani B, Stadtmauer EA, Thakar MS, Sorror M.: Differential use of the hematopoietic cell transplantation-comorbidity index among adult and pediatric transplant physicians. Leuk Lymphoma Oct 2022.

Bashir Q, Nishihori T, Pasquini MC, Martens MJ, Wu J, Alsina M, Anasetti C, Brunstein C, Dawson P, Efebera Y, Gasparetto C, Geller N, Giralt S, Hall AC, Koreth J, McCarthy P, Scott E, Stadtmauer EA, Vesole DH, Hari P.: A Multicenter Phase II, Double-Blind, Placebo-Controlled Trial of Maintenance Ixazomib After Allogeneic Transplantation for High-Risk Multiple Myeloma: Results of the Blood and Marrow Transplant Clinical Trials Network 1302 Trial. Transplant Cell Ther Jul 2022.

Matthews AH, Perl AE, Luger SM, Loren AW, Gill SI, Porter DL, Babushok DV, Maillard IP, Carroll MP, Frey NV, Hexner EO, Martin ME, McCurdy SR, Stadtmauer EA, Paralkar VR, Bruno XJ, Hwang WT, Margolis D, Pratz KW.: Real-world effectiveness of CPX-351 vs venetoclax and azacitidine in acute myeloid leukemia. Blood Adv 6: 3997-4005, Jul 2022.

Susanibar Adaniya S, Stadtmauer EA, Cohen AD.: CAR T cell therapy for multiple myeloma: What have we learned? Leukemia June 2022.

Patel SS, Ahn KW, Khanal M, Bupp C, Allbee-Johnson M, Majhail NS, Hamilton BK, Rotz SJ, Hashem H, Beitinjaneh A, Lazarus HM, Krem MM, Prestidge T, Bhatt NS, Sharma A, Gadalla SM, Murthy HS, Broglie L, Nishihori T, Freytes CO, Hildebrandt GC, Gergis U, Seo S, Wirk B, Pasquini MC, Savani BN, Sorror ML, Stadtmauer EA, Chhabra S.: Noninfectious Pulmonary Toxicity after Allogeneic Hematopoietic Cell Transplantation. Transplant Cell Ther June 2022.

D'Souza A, Brazauskas R, Stadtmauer EA, Pasquini MC, Hari P, Bashey A, Callander N, Devine S, Efebera Y, Ganguly S, Gasparetto C, Geller N, Horowitz MM, Koreth J, Landau H, Brunstein C, McCarthy P, Qazilbash MH, Giralt S, Krishnan A, Flynn KE.: Trajectories of quality of life recovery and symptom burden after autologous hematopoietic cell transplantation in multiple myeloma. Am J Hematol May 2022.

Abou-Ismail MY, Fraser R, Allbee-Johnson M, Metheny L 3rd, Ravi G, Ahn KW, Bhatt NS, Lazarus HM, de Lima M, El Jurdy N, Hematti P, Beitinjaneh AM, Nishihori T, Badawy SM, Sharma A, Pasquini MC, Savani BN, Sorror ML, Stadtmauer EA, Chhabra S.: Does recipient body mass index inform donor selection for allogeneic haematopoietic cell transplantation? Br J Haematol May 2022.

back to top
Last updated: 12/06/2022
The Trustees of the University of Pennsylvania

The Penn Difference

  • Individualized Treatment Plan
  • Expert Treatment Team Knowledgeable in Myeloproliferative Disorders
  • State-of-the-Art Personalized Diagnostic Testing
  • Access to Newest Therapies Through Clinical Trials
  • Comprehensive Bone Marrow Transplantation Service
  • Integrated Care by a Multidisciplinary Treatment Team

Make an Appointment

New Patients:
Abramson Cancer Center
Perelman Center for Advanced Medicine
2nd Floor, West Pavilion
Philadelphia, PA 19104
Phone: 215-615-5858 option 2
Fax: 215-615-5889

Current Patients:
Contact your doctor directly

For General Inquiries:
Call the Myeloproliferative Neoplasms Program at  215-614-1847